Therefore, the ability of physapubescin to down-regulate HIF-1/2α and vimentin levels led to anti-angiogenesis effects, which suggests that physapubescin may be particularly effective against highly vascularized RCC tumors. This evidence concerns the gene HIF1A and renal cell carcinoma.